The effect of antihypertensive treatment on patients with diabetes depends on the values of blood pressure: a systematic survey and meta-analyses

Czech version

Authors: Jiří Widimský Sr
Authors‘ workplace: Klinika kardiologie IKEM, Praha
Published in: Vnitř Lék 2016; 62(4): 312-315
Category: Reviews

Komentář ke článku Brunström M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ 2016; 52: i717

Overview

What was already known about these problems before the publication of the Northern Swedish study? Hypertension is the most important risk factor for mortality and cardiovascular disease on a global scale. Patients with diabetes mellitus demonstrate an increased risk for cardiovascular disease and they often also have hypertension at the same time. Antihypertensive treatment reduces the risk of cardiovascular diseases in patients with diabetes, however an optimum value of blood pressure is a matter of debate. What is the special contribution of the Swedish study? Antihypertensive treatment in patients with diabetes and a systolic pressure higher than 140 mm Hg brings with it a decreased risk of mortality and cardiovascular disease. Antihypertensive treatment in patients with diabetes and a systolic lower than 140 mm Hg, however, brings with it an increased risk of mortality and cardiovascular disease. The interaction between systolic pressure values before the treatment and during it is significant.

Key words:
antihypertensive treatment – diabetes mellitus – blood pressure dependence

Sources

1. Brunström M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ 2016; 52: i717. Dostupné z DOI: <http://doi: 10.1136/bmj.i717>.

2. Cushman WC, Evans GW, Byington RP et al. [ACCORD Study Group]. Effect of intensive blood pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362(17): 1575–1585.

3. Dahlöf B, Sever PS, Poulter NE et al. [ASCOT Investigators]. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895–906.

4. Filipovský J, Widimský J jr, Ceral J et al. Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2012; 58(10): 785–801.

5. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359(23): 2417–2428.

6. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345(12): 851–860.

7. Maliha G, Townsend RR. SGLT2 inhibitors: their potential reduction in blood pressure. J Am Soc Hypertens 2015; 9(1): 48–53.

8. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31(7): 1281–1357.

9. Oxlund CS, Henriksen JE, Tarnow L et al. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens 2013; 31(10): 2094–2102.

10. Patel A, MacMahon S, Chalmers J et al. [ADVANCE Collaborative Group]. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370(9590): 829–840.

11. Staessen JA, Thijs L, Fagard R et al. [Systolic Hypertension in Europe (Syst-Eur) Trial Investigators]. Effects of immediate versus delayed antihypertensive therapy outcome in the Systolic Hypertension in Europe Trial. J Hypertension 2004; 22(4): 847–857.

12. Widimský J. Studie SPRINT. Randomizovaná studie porovnávající intenzivní oproti standardní kontrole systolického krevního tlaku. Vnitř Lék 2016; 62(1): 44–47.

13. [UK Prospective Diabetes Study Group]. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317(7160): 703–713.

14. Wright JT Jr, Williamson JD, Whelton PK et al. [SPRINT Research Group]. A randomized trial of intenzive versus standard blood pressure control. N Engl J Med 2015; 373(22): 2103–2116.

15. Zinman B, Wanner CH, Lachin JM et al. [EMPA-REG OUTCOME]. Empagliflozin, Cardiovascular Outcomes and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373(22): 2117–2128.